Seventure Partners
Edit

Seventure Partners

https://www.seventure.fr
Last activity: 09.01.2025
Active
With over €660m in assets under management as of the end of 2016, Seventure Partners is a leading venture capital firm in Europe. Since 1997, Seventure Partners has invested in innovative businesses with high growth potential in Digital technologies, especially fintech & insurtech, in France and Germany, and in the Life sciences field across Europe, North America ans Asia. Investments can range between €500k and €10m per round, or up to €20m per company, from early to late stage. Seventure is a subsidiary of Natixis Global Asset Management. Natixis is the corporate investment management and financial services arm of Groupe BPCE, the second-largest French bank. For more details: www.seventure.com
Followers
9.92K
News
244
Portfolio
4
Mentions
70
Location: France, Ile-de-France, Paris
Employees: 11-50
Founded date: 1997
Investment Type: Venture Capital
Investment Stage: Series A; Series B; Series C; Series D; Series E; Series F; Series G; Series H

Portfolio 4

DateNameWebsiteTotal RaisedLocation
30.03.2023Glopalmerchants.glopal.com$26.26MFrance, Il...
29.03.2023Glopalglopal.com$21.78MMetropolit...
05.05.2021Cytoki Pha...cytokipharma.com$45MDenmark, G...
10.11.2014Humedics G...humedics.eu$7.83MGermany, B...

News 244

DateTitleDescription
05.12.2023Eligo Bioscience Raises $30 Million To Write a Novel Chapter for Genetic MedicinesEligo Bioscience, a pioneering gene-editing company focused on addressing diseases driven by the expression of bacterial genes from the microbiome, has announced a successful...
31.10.2023MaaT Pharma to Present Preclinical Data at SITC on MaaT034, an Artificial Intelligence-Generated Product Aimed at Improving Patients’ Responses to ImmunotherapiesMaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotech company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to...
30.10.2023Enterome Selected to The Leukemia & Lymphoma Society’s Therapy Acceleration ProgramEnterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its unique Mimicry...
26.10.2023MaaT Pharma Announces Positive Outcome Following DSMB Review Reinforcing Confidence in Phase 3 On-Going Trial in Acute Graft-versus-Host Disease with MaaT013MaaT Pharma today announced that the DSMB unanimously recommended that the open-label, single arm pivotal Phase 3 clinical trial evaluating MaaT013 in acute Graft-versus-Host...
26.10.2023Pharma announces positive outcome following DSMB review reinforcing confidence in phase 3 on-going trial.Maat Pharma announces that the DSMB unanimoulsy recommended that the open-label, single arm pivotal Phase 3 clinical trial evaluating MaaT013 in acute Graft-versus-Host Disease...
09.10.2023CorWave announces the grand opening of its manufacturing facility on the banks of the Seine, next to ParisA French company that develops and manufactures innovative cardiac assist devices, held the grand opening of its new facility on the banks of the Seine in Clichy, next to...
29.08.2023Citryll Announces Appointments of Eduardo Bravo as CEO and Tim Schenk as CBOCitryll, a clinical-stage biotech company developing first-in-class therapeutics to treat immune-mediated inflammatory diseases, today announced the appointment of Eduardo...
24.08.2023Alliance Promotion Microbiote applauds the new legislation securing stool collection in FranceThe Alliance Promotion Microbiote (APM), a prominent player dedicated to the development, production, and commercialization of therapeutic microbiome-based innovations,...
30.06.2023Enterome announces first patient dosed in a Phase 1/2 trial with third OncoMimics™ immunotherapy, EO4010, in Metastatic Colorectal CancerEnterome today announces that the first patient was dosed in the Phase 1/2 'AUDREY' trial evaluating EO4010, the Company's third OncoMimics™ candidate, for the treatment of...
14.06.2023Enterome’s new OncoMimics™ immunotherapy, EO2463, demonstrates early efficacy and favorable safety in Phase 1/2 trial for indolent non-Hodgkin lymphomaEnterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its unique Mimicry...
Show more

Mentions in press and media 70

DateTitleDescription
09.01.2025FIRE1: $120 Million Funding Raised For Transforming Heart Failure CareFIRE1 – a leading connected medical device solutions company – announced the completion of a $120 million financing round to accelerate the company’s mission to transform the lives of millions of people living with heart failure. The fundin...
08.01.2025FIRE1 Secures $120M for Heart Failure Management PlatformWhat You Should Know: – FIRE1, a connected medical device company, announced it has secured $120M in funding to advance its mission to transform the lives of millions of people living with heart failure. The round was led by Polaris Partner...
07.01.2025FIRE1 heats up with $120M for its heart failure monitor implantThings are heating up for FIRE1, which posted a $120 million funding round to support its implant for tracking the hidden signs of heart failure. The Dublin-based company also announced that the FDA has handed down a breakthrough designatio...
07.01.2025FIRE1 Secures $120M FinancingFIRE1, a Dublin, Ireland-based connected medical device solutions company, raised $120M in funding. The round was led by Polaris Partners and Elevage Medical Technologies, joined by new investors Sands Capital and Longitude Capital, and exi...
10.12.2024Citryll's €85 Million Boost: A New Dawn for Inflammatory Disease TreatmentIn the world of biotech, funding is the lifeblood. Recently, Dutch startup Citryll secured a significant €85 million in Series B funding. This financial windfall is not just a number; it represents hope for countless patients battling immun...
09.12.2024Citryll Raises EUR 85M in Series B FundingCitryll, an Oss, The Netherlands-based biotech company developing a new approach to treating immune-mediated inflammatory diseases by targeting Neutrophil Extracellular Traps (NETs), raised €85M in Series B funding. The round was led by Joh...
09.12.2024Oss-based Citryll secures €85 million Series B funding to advance NET-targeting therapyDutch startup Citryll, a biotech innovator in immune-mediated inflammatory diseases, has raised €85 million in a Series B funding round. The financing was co-led by Johnson & Johnson Innovation (through its corporate venture capital org...
20.06.2024YesWeHack Secures €26M in Series C Funding, Embarking on a New Chapter of Growth and InnovationYesWeHack, a pioneering bug bounty and vulnerability management platform based in Paris, has successfully raised a substantial €26 million in Series C funding. This significant funding round was spearheaded by Wendel, a prominent investment...
18.06.2024YesWeHack: Bug Bounty And Vulnerability Management Platform Closes €26 MillionYesWeHack, a global Bug Bounty and vulnerability management platform, announced a €26 million Series C funding round. Wendel led the round, which included new investors like Adelie and Seventure Partners and reinvestment from Bpifrance, Ope...
13.07.2023Rostock-based insurtech hepster raises €10 million to focus on profitability and sustainable growthGerman embedded insurtech hepster has raised €10 million in a Series B funding round. Via its API it enables companies 'to integrate needs-based and individual insurance into their offerings', including mobility, electronics, equipment, tra...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In